STOCK TITAN

Ibio - IBIO STOCK NEWS

Welcome to our dedicated page for Ibio news (Ticker: IBIO), a resource for investors and traders seeking the latest updates and insights on Ibio stock.

iBio, Inc. (IBIO) is a biotechnology innovator providing end-to-end CDMO services and AI-driven solutions for biotherapeutics development. This page serves as the definitive source for all official company announcements, regulatory filings, and operational updates.

Investors and industry observers will find timely access to earnings reports, strategic partnerships, regulatory milestones, and technology advancements related to iBio's vaccine development and precision antibody platforms. Our curated feed ensures transparent tracking of the company's progress in accelerating biopharmaceutical production from discovery to commercialization.

All content is sourced directly from iBio's corporate communications, maintaining factual accuracy and compliance with financial disclosure standards. Bookmark this page for efficient monitoring of IBIO's developments in artificial intelligence applications for drug discovery, manufacturing expansions, and clinical trial updates.

Rhea-AI Summary
iBio, Inc. (NYSEA:IBIO) announced a public offering of 2,250,000 shares of common stock and accompanying Series C and Series D warrants, resulting in gross proceeds of approximately $4.5 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-50%
Tags
-
News
Rhea-AI Summary
iBio, Inc. (IBIO) has approved a 20-to-1 reverse split of its common stock, effective on November 29, 2023. The reverse stock split will result in every 20 shares being combined into one share, reducing the outstanding shares from 28,100,733 to 1,405,036. The split will not affect ownership percentage except for holders of fractional shares. The exercise prices of stock options, warrants, and equity incentive plans will be adjusted accordingly.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-31.03%
Tags
none
-
Rhea-AI Summary
iBio, Inc. has announced the launch of ShieldTx, an AI-powered antibody masking technology that enables targeted delivery to diseased tissue. The technology aims to overcome challenges in complex targets, safety, and developability in antibody discovery and development. iBio used ShieldTx to develop masks for its MUC16-targeted bispecific antibody candidates. The technology deactivates the antibodies until they encounter a specific enzyme in the target tissue, reducing off-tissue side effects and enhancing therapeutic safety. ShieldTx can be applied to cancer therapeutics and autoimmune and inflammatory diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.85%
Tags
none
Rhea-AI Summary
iBio's VP of Platform Technologies to present on enhancing T-cell engagers at the Festival of Biologics
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.14%
Tags
none
-
Rhea-AI Summary
iBio clarifies its post-effective amendment to its Form S-3 on Form S-1, maintaining the registration of common stock warrants issued and outstanding. No new securities are being registered.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.33%
Tags
none
-
Rhea-AI Summary
iBio files annual report with the SEC, reporting $nil in revenues for FY 2023 compared to $1.9 million in FY 2022. Operating expenses decrease by 7% to $29.3 million. Consolidated net loss increases by $14.6 million to $65.0 million. iBio holds $4.3 million in cash and cash equivalents and $3.3 million in restricted cash. The audited financial statements contain an audit opinion regarding the Company's ability to continue as a going concern. The maturity date of the Credit Agreement is extended to December 31, 2023, providing time to close the sale of the CDMO Facility. No assurance of closing conditions being satisfied. The divestiture of iBio's manufacturing business in Texas will extend cash runway for AI drug discovery platform and immunotherapy pipeline.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
iBio extends maturity date of credit agreement to December 31, 2023, allowing time to close pending sale of CDMO facility. Sale of facility will complete divestiture of contract development and manufacturing business. Positive for stock price.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.06%
Tags
none
-
Rhea-AI Summary
iBio announces positive pre-clinical data for three immuno-oncology candidates, including a 43% reduction in tumor growth with anti-EGFRvIII antibody and a 36% reduction in tumor size with TROP-2 x CD3 antibody.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.67%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.35%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.74%
Tags
none
Ibio

NYSE:IBIO

IBIO Rankings

IBIO Stock Data

8.96M
9.11M
7.21%
26.65%
4.6%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEW YORK